Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-19 · accession 0001681643-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-23 | 2026-02-19 | REGN | Zoghbi Huda Y | Dir | S - Sale+OE | $781.33 | -1,638 | 3,242 | -34% | -$1.28M |
| D | 2026-02-23 | 2026-02-19 | REGN | Zoghbi Huda Y | Dir | M - OptEx | $376.69 | +1,638 | 3,341 | +96% | +$617.0K |
| D | 2026-02-23 | 2026-02-19 | REGN | Zoghbi Huda Y | Dir | M - OptEx | $0.00 | -1,638 | 800 | -67% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-19 | S | D | 4 | $790.00 | 1,703 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-19 | S | D | 160 | $784.45 | 1,763 | D | — | — | (F8) Represents volume-weighted average price of sales of 160 shares of Company stock on February 19, 2026 at prices ranging from $784.14 to $784.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. |
| 3 | Common | Common Stock | 2026-02-19 | M | A | 1,638 | $376.69 | 3,341 | D | — | — | |
| 4 | Common | Common Stock | 2026-02-19 | S | D | 56 | $785.61 | 1,707 | D | — | — | (F9) Represents volume-weighted average price of sales of 56 shares of Company stock on February 19, 2026 at prices ranging from $785.60 to $785.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. |
| 5 | Common | Common Stock | 2026-02-19 | S | D | 49 | $774.68 | 3,292 | D | — | — | |
| 6 | Common | Common Stock | 2026-02-19 | S | D | 220 | $783.29 | 1,923 | D | — | — | (F7) Represents volume-weighted average price of sales of 220 shares of Company stock on February 19, 2026 at prices ranging from $783.00 to $783.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. |
| 7 | Common | Common Stock | 2026-02-19 | S | D | 298 | $782.10 | 2,143 | D | — | — | (F6) Represents volume-weighted average price of sales of 298 shares of Company stock on February 19, 2026 at prices ranging from $782.01 to $782.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. |
| 8 | Common | Common Stock | 2026-02-19 | S | D | 209 | $781.28 | 2,441 | D | — | — | (F5) Represents volume-weighted average price of sales of 209 shares of Company stock on February 19, 2026 at prices ranging from $781.10 to $781.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. |
| 9 | Common | Common Stock | 2026-02-19 | S | D | 331 | $780.45 | 2,650 | D | — | — | (F4) Represents volume-weighted average price of sales of 331 shares of Company stock on February 19, 2026 at prices ranging from $780.06 to $780.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. |
| 10 | Common | Common Stock | 2026-02-19 | S | D | 208 | $779.55 | 2,981 | D | — | — | (F3) Represents volume-weighted average price of sales of 208 shares of Company stock on February 19, 2026 at prices ranging from $779.10 to $779.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. |
| 11 | Common | Common Stock | 2026-02-19 | S | D | 53 | $778.47 | 3,189 | D | — | — | (F2) Represents volume-weighted average price of sales of 53 shares of Company stock on February 19, 2026 at prices ranging from $778.46 to $778.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. |
| 12 | Common | Common Stock | 2026-02-19 | S | D | 50 | $775.50 | 3,242 | D | — | — | |
| 13 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-02-19 | M | D | 1,638 | $0.00 | 800 | D | $376.69 · — to 2027-01-03 | 1,638 Common Stock | (F10) The stock option vested in three equal annual installments, commencing one year after the date of grant. |